Internal Medicine, Hematology & Oncology · Sarasota, FL
NPI
1306937669
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
3830 Bee Ridge Rd, Suite 301
Sarasota, FL, 34233
Phone (941) 923-1872
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.4M
172,510 services
Medicare patients, 2024
415
Average age 77
Drug cost, 2024
$8.9M
1,898 prescriptions
Company payments, 2025
$4,403
From 49 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Manjesh Lingamurthy was code J1439 (injection, ferric carboxymaltose, 1 mg), 53,250 times for 27 patients. In total Manjesh Lingamurthy billed 172,510 services in 92 codes, and Medicare paid $2.4M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-11-15.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 53,250 | 27 | $0.88 | $47K |
| J0897 Injection, denosumab, 1 mg | Office | 12,600 | 70 | $20.39 | $257K |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 6,130 | 18 | $5.32 | $33K |
| J1201 Injection, cetirizine hydrochloride, 0.5 mg | Office | 1,600 | 33 | $11.70 | $19K |
| 85025 Blood Count | Office | 1,556 | 304 | $7.55 | $12K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,394 | 59 | $0.09 | $125 |
| 99213 Office E&M - Established | Office | 625 | 217 | $62.34 | $39K |
| 99214 Office E&M - Established | Office | 508 | 206 | $91.49 | $46K |
| 96372 Injection Administration | Office | 504 | 109 | $10.53 | $5,309 |
| 96375 Injection Administration | Office | 416 | 59 | $11.34 | $4,716 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 390 | 13 | $0.74 | $290 |
| 99215 Office E&M - Established | Office | 232 | 125 | $132.92 | $31K |
| 96365 Intravenous Infusion, Hydration | Office | 177 | 71 | $45.84 | $8,114 |
| 96413 Chemotherapy Administration | Office | 174 | 30 | $94.41 | $16K |
| J3489 Injection, zoledronic acid, 1 mg | Office | 149 | 27 | $5.20 | $775 |
By year: 2022 $2.5M for 176,115 services; 2023 $2.5M for 158,823 services; 2024 $2.4M for 172,510 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 1,556 | 304 | $7.55 | $12K |
Medicare prescription drug claims, 2024
In 2024, the drug Manjesh Lingamurthy prescribed most often to Medicare patients was Letrozole, with 144 prescriptions and refills. In total Manjesh Lingamurthy wrote 1,898 Medicare prescriptions that cost $8.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Letrozole Generic | 144 | 409 | 46 | $3,586 |
| Lenalidomide Generic | 103 | 103 | 13 | $1.2M |
| Hydroxyurea Generic | 94 | 242 | 28 | $3,357 |
| Prednisone Generic | 91 | 163 | 31 | $692 |
| Anastrozole Generic | 81 | 213 | 22 | $1,455 |
| Octagam Immun Globg(Igg)/Malt/Iga Ov50 | 76 | 76 | Under 11 | $499K |
| Ondansetron Odt Ondansetron | 67 | 67 | 58 | $2,963 |
| Xtandi Enzalutamide | 60 | 60 | Under 11 | $811K |
| Acyclovir Generic | 58 | 172 | 27 | $1,016 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 47 | 47 | 13 | $1,388 |
| Oxycodone Hcl Generic | 36 | 36 | 12 | $858 |
| Dexamethasone Generic | 33 | 79 | 16 | $1,450 |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 31 | 31 | Under 11 | $1,269 |
| Eliquis Apixaban | 30 | 47 | Under 11 | $26K |
| Jakafi Ruxolitinib Phosphate | 30 | 30 | Under 11 | $521K |
Brand drugs: - claims; generic drugs: 1,185 claims; opioid claims: 150.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Manjesh Lingamurthy $4,403 ($4,403 in general payments such as food, travel and fees) from 49 companies. The largest payer was Pfizer Inc. with $436.
| Company | Payments | Amount |
|---|---|---|
| Pfizer Inc. PFE | 21 | $436 |
| Celgene Corporation BMY | 9 | $406 |
| Janssen Biotech, Inc. JNJ | 26 | $331 |
| Novartis Pharmaceuticals Corporation NVS | 18 | $262 |
| Daiichi Sankyo Inc. 4568.T | 9 | $253 |
| Merck Sharp & Dohme LLC MRK | 9 | $218 |
| Gilead Sciences, Inc. GILD | 8 | $155 |
| AstraZeneca Pharmaceuticals LP AZN | 7 | $152 |
| BeOne Medicines USA, Inc. ONC | 7 | $139 |
| GlaxoSmithKline, LLC. GSK | 5 | $131 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.